Clinical Trial Update: Reverse HER2-negative Immune Resistant Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial recruiting to address immune resistance in HER2-negative breast cancer, sponsored by Fudan University.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Fudan University | Conditions: HER2 Negative Breast Cancer | Phase 2 | Status: RECRUITING